We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all.
In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
As a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals.
After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer.
When LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. “A Gilead medicine saved the life of a loved one, so I was excited to begin a career here and to contribute in any way I could,” LJ says.
When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit.
We sat down with Dan Murphy and Dr. Jeffrey Lazarus to discuss the work that needs to be done to meet the United Nations' (U.N.) goal of ending the HIV epidemic by 2030 and to fully meet the needs of people living with HIV around the world.
Many of the communities who could most benefit from pre-exposure prophylaxis (PrEP) for HIV prevention haven’t been included in clinical trial design and execution over the years – but Gilead’s PURPOSE studies made their inclusion a primary goal.
As a way to support those impacted by Monday’s devastating earthquake in Türkiye and Syria, the Gilead Foundation is donating $1 million for on-the-ground relief efforts.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...